MaxCyte Inc (MXCT)

Currency in USD
1.280
+0.030(+2.40%)
Closed·
1.2800.000(0.00%)
·
MXCT is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1.2301.320
52 wk Range
0.6431.800
Key Statistics
Prev. Close
1.25
Open
1.3
Day's Range
1.23-1.32
52 wk Range
0.643-1.8
Volume
1.67M
Average Volume (3m)
1.02M
1-Year Change
-24.7059%
Book Value / Share
1,46
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
MXCT Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
4.108
Upside
+220.90%
Members' Sentiments
Bearish
Bullish
ProTips
Holds more cash than debt on its balance sheet

MaxCyte Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Analyst Ratings

5 Buy
1 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 4.108
(+220.90% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Stifel
Buy4.00+212.50%-MaintainNov 12, 2026
BTIG
Hold---MaintainAug 24, 2026
Stifel
Buy4.00+212.50%9.00MaintainMar 25, 2026
Craig-Hallum
Buy5.00+290.63%7.00MaintainMar 25, 2026
William Blair
Hold---MaintainMar 23, 2026

MaxCyte Inc Earnings Call Summary for Q3/2026

  • MaxCyte Q3 revenue surged 49% YoY to $10.2M, beating estimates by 44.6%; adjusted EPS loss of $0.05 beat forecast by 39.4%
  • Gross margin improved to 83% from 77% YoY; operating expenses fell 25% as YTD net loss nearly halved to $18M from $35M prior year
  • Company raised FY2026 revenue guidance to at least $34.5M, including $28M core revenue and $6.5M from SPL milestones and royalties
  • Planned Akron Bio acquisition expected to nearly double pro forma 2026 revenue above $60M and cut annual cash burn below $10M in 2027
  • Shares rose 6.15% premarket to $1.38; management cited return to growth in H2 2026 and improved visibility from late-stage programs
Last Updated: 2026/11/10, 16:32
Read Full Transcript

Earnings

Latest Release
Nov 10, 2026
EPS / Forecast
-0,05 / -0,08
Revenue / Forecast
10,15M / 7,02M
EPS Revisions
Last 90 days

MXCT Income Statement

Compare MXCT to Peers and Sector

Metrics to compare
MXCT
Peers
Sector
Relationship
P/E Ratio
−4.8x−0.7x−0.2x
PEG Ratio
−0.12−0.040.00
Price/Book
0.9x4.4x2.6x
Price / LTM Sales
3.9x6.0x2.7x
Upside (Analyst Target)
220.9%146.4%69.6%
Fair Value Upside
Unlock6.6%11.7%Unlock

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. The company has strategic partnership with VectorBuilder focused on co-developing a new gene delivery solution. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
17,34M16,81%21,68M
Other Institutional Investors
48,50M47,00%60,63M
Public Companies & Retail Investors
37,36M36,20%46,70M
Total
103,21M100,00%129,01M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Capricorn Fund Managers Limited7,95%8 200 00010 250
Liontrust Asset Management PLC4,92%5 081 4036 352

FAQ

What Is the MaxCyte (MXCT) Stock Price Today?

The MaxCyte stock price today is 1,280 USD.

What Stock Exchange Does MaxCyte Trade On?

MaxCyte is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for MaxCyte?

The stock symbol for MaxCyte is "MXCT."

What Is the MaxCyte Market Cap?

As of today, MaxCyte market cap is 134,230M USD.

What Is MaxCyte's Earnings Per Share (TTM)?

The MaxCyte EPS (TTM) is -0,26.

When Is the Next MaxCyte Earnings Date?

MaxCyte will release its next earnings report on Mar 16, 2027.

From a Technical Analysis Perspective, Is MXCT a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has MaxCyte Stock Split?

MaxCyte has split 0 times.

How Many Employees Does MaxCyte Have?

MaxCyte has 91 employees.

What is the current trading status of MaxCyte (MXCT)?

As of Nov 19, 2026, MaxCyte (MXCT) is trading at a price of 1,280 USD, with a previous close of 1,250 USD. The stock has fluctuated within a day range of 1,230 USD to 1,320 USD, while its 52-week range spans from 0,643 USD to 1,800 USD.

What Is MaxCyte (MXCT) Price Target According to Analysts?

The average 12-month price target for MaxCyte is 4,108 USD, with a high estimate of 5 USD and a low estimate of 2.43 USD. 5 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +220,90% Upside potential.

What Is the MXCT Premarket Price?

MXCT's last pre-market stock price is 1,318 USD. The pre-market share volume is 31 230,000, and the stock has decreased by 0,068, or 5,440%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.